NL-OMON55193已完成不适用
Therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease - TUMMY
Maxima Medisch Centrum0 个研究点目标入组 160 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •age *18 years, maintenance therapy of vedolizumab (>14 weeks), diagnosed with
- •Crohn's disease (DBC 601) or colitis ulcerosa (DBC602)
排除标准
- •age <18 years, induction therapy with vedolizumab (<14 weeks), incapable of
研究者
相似试验
尚未招募
不适用
Therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel diseaseNL-OMON28041one160
招募中
不适用
Monitoring of Vedolizumab Infusion Therapy response with fecal calprotectin, ultrasound and trough serum level in Ulcerative colitis. A multicentric, prospective non-interventional StudyK51Ulcerative colitisDRKS00014249Internistische Gemeinschaftspraxis50
已完成
不适用
Prospective evaluation of vedolizumab-effects in patients with inflammatory bowel diseasesulcerative colitis and Crohn's diseaseJPRN-UMIN000039916Saitama Medical Center, Saitama Medical University50
招募中
不适用
Prospective evaluation of vedolizumab-effects and safety in patients with inflammatory bowel diseases (VED IBD Cohort Study)JPRN-UMIN000040175Saitama Medical Center, Saitama Medical University50
暂停
不适用
Pharmacokinetics and efficacy of Vedolizumab in inflammatory bowel diseasesulcerative colitis and Crohn's diseaseJPRN-UMIN000045425Shiga University of Medical Science50